145 related articles for article (PubMed ID: 36386885)
1. Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model.
Ren X; Corrigan DT; Zang X
STAR Protoc; 2022 Dec; 3(4):101818. PubMed ID: 36386885
[TBL] [Abstract][Full Text] [Related]
2. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target.
Wei Y; Ren X; Galbo PM; Moerdler S; Wang H; Sica RA; Etemad-Gilbertson B; Shi L; Zhu L; Tang X; Lin Q; Peng M; Guan F; Zheng D; Chinai JM; Zang X
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34244312
[TBL] [Abstract][Full Text] [Related]
3. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.
Bhatt RS; Berjis A; Konge JC; Mahoney KM; Klee AN; Freeman SS; Chen CH; Jegede OA; Catalano PJ; Pignon JC; Sticco-Ivins M; Zhu B; Hua P; Soden J; Zhu J; McDermott DF; Arulanandam AR; Signoretti S; Freeman GJ
Cancer Immunol Res; 2021 Feb; 9(2):156-169. PubMed ID: 33229411
[TBL] [Abstract][Full Text] [Related]
4. HHLA2 immune-regulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
[TBL] [Abstract][Full Text] [Related]
5. Mystery Checkpoint Revealed: KIR3DL3 Finally Found a Ligand in HHLA2.
Campbell KS
Cancer Immunol Res; 2021 Feb; 9(2):128. PubMed ID: 33536266
[TBL] [Abstract][Full Text] [Related]
6. Conservation, Extensive Heterozygosity, and Convergence of Signaling Potential All Indicate a Critical Role for KIR3DL3 in Higher Primates.
Leaton LA; Shortt J; Kichula KM; Tao S; Nemat-Gorgani N; Mentzer AJ; Oppenheimer SJ; Deng Z; Hollenbach JA; Gignoux CR; Guethlein LA; Parham P; Carrington M; Norman PJ
Front Immunol; 2019; 10():24. PubMed ID: 30745901
[TBL] [Abstract][Full Text] [Related]
7. Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells.
Palmer WH; Leaton LA; Campos Codo A; Crute B; Roest J; Zhu S; Petersen J; Tobin RP; Hume PS; Stone M; van Bokhoven A; Gerich ME; McCarter MD; Zhu Y; Janssen WJ; Vivian JP; Trowsdale J; Getahun A; Rossjohn J; Cambier J; Loh L; Norman PJ
Sci Immunol; 2023 Jun; 8(84):eade5343. PubMed ID: 37390222
[TBL] [Abstract][Full Text] [Related]
8. KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.
Li Y; Lv C; Yu Y; Wu B; Zhang Y; Lang Q; Liang Z; Zhong C; Shi Y; Han S; Xu F; Tian Y
J Adv Res; 2023 May; 47():137-150. PubMed ID: 35933091
[TBL] [Abstract][Full Text] [Related]
9. Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.
Ying H; Xu J; Zhang X; Liang T; Bai X
EBioMedicine; 2022 May; 79():103987. PubMed ID: 35439678
[TBL] [Abstract][Full Text] [Related]
10. Regulation of KIR3DL3 Expression via Mirna.
Nutalai R; Gaudieri S; Jumnainsong A; Leelayuwat C
Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31405037
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of KIR3DL3.
Trundley AE; Hiby SE; Chang C; Sharkey AM; Santourlidis S; Uhrberg M; Trowsdale J; Moffett A
Immunogenetics; 2006 Jan; 57(12):904-16. PubMed ID: 16391939
[TBL] [Abstract][Full Text] [Related]
12. Three structurally and functionally divergent kinds of promoters regulate expression of clonally distributed killer cell Ig-like receptors (KIR), of KIR2DL4, and of KIR3DL3.
Trompeter HI; Gómez-Lozano N; Santourlidis S; Eisermann B; Wernet P; Vilches C; Uhrberg M
J Immunol; 2005 Apr; 174(7):4135-43. PubMed ID: 15778373
[TBL] [Abstract][Full Text] [Related]
13. Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.
Chan WK; Kung Sutherland M; Li Y; Zalevsky J; Schell S; Leung W
Clin Cancer Res; 2012 Nov; 18(22):6296-305. PubMed ID: 23014531
[TBL] [Abstract][Full Text] [Related]
14. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
Romagné F; André P; Spee P; Zahn S; Anfossi N; Gauthier L; Capanni M; Ruggeri L; Benson DM; Blaser BW; Della Chiesa M; Moretta A; Vivier E; Caligiuri MA; Velardi A; Wagtmann N
Blood; 2009 Sep; 114(13):2667-77. PubMed ID: 19553639
[TBL] [Abstract][Full Text] [Related]
15. Nature of allelic sequence polymorphism at the KIR3DL3 locus.
Jones DC; Hiby SE; Moffett A; Trowsdale J; Young NT
Immunogenetics; 2006 Aug; 58(8):614-27. PubMed ID: 16823588
[TBL] [Abstract][Full Text] [Related]
16. Report from the Killer-cell Immunoglobulin-like Receptors (KIR) component of the 17th International HLA and Immunogenetics Workshop.
Misra MK; Augusto DG; Martin GM; Nemat-Gorgani N; Sauter J; Hofmann JA; Traherne JA; González-Quezada B; Gorodezky C; Bultitude WP; Marin W; Vierra-Green C; Anderson KM; Balas A; Caro-Oleas JL; Cisneros E; Colucci F; Dandekar R; Elfishawi SM; Fernández-Viña MA; Fouda M; González-Fernández R; Große A; Herrero-Mata MJ; Hollenbach SQ; Marsh SGE; Mentzer A; Middleton D; Moffett A; Moreno-Hidalgo MA; Mossallam GI; Nakimuli A; Oksenberg JR; Oppenheimer SJ; Parham P; Petzl-Erler ML; Planelles D; Sánchez-García F; Sánchez-Gordo F; Schmidt AH; Trowsdale J; Vargas LB; Vicario JL; Vilches C; Norman PJ; Hollenbach JA
Hum Immunol; 2018 Dec; 79(12):825-833. PubMed ID: 30321631
[TBL] [Abstract][Full Text] [Related]
17. The Importance of HHLA2 in Solid Tumors-A Review of the Literature.
Kula A; Koszewska D; Kot A; Dawidowicz M; Mielcarska S; Waniczek D; Świętochowska E
Cells; 2024 May; 13(10):. PubMed ID: 38786018
[TBL] [Abstract][Full Text] [Related]
18. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.
He Y; Liu S; Mattei J; Bunn PA; Zhou C; Chan D
Drug Des Devel Ther; 2018; 12():981-986. PubMed ID: 29731605
[TBL] [Abstract][Full Text] [Related]
19. NK cell receptor gene of the KIR family with two IG domains but highest homology to KIR receptors with three IG domains.
Selvakumar A; Steffens U; Dupont B
Tissue Antigens; 1996 Oct; 48(4 Pt 1):285-94. PubMed ID: 8946682
[TBL] [Abstract][Full Text] [Related]
20. The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer.
Pende D; Biassoni R; Cantoni C; Verdiani S; Falco M; di Donato C; Accame L; Bottino C; Moretta A; Moretta L
J Exp Med; 1996 Aug; 184(2):505-18. PubMed ID: 8760804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
